Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

There is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. Herein, we explored the outcomes of patients treated with venetoclax and azacitidine who achieved composite complete remissi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratz, Keith W., Jonas, Brian A., Pullarkat, Vinod, Recher, Christian, Schuh, Andre C., Thirman, Michael J., Garcia, Jacqueline S., DiNardo, Courtney D., Vorobyev, Vladimir, Fracchiolla, Nicola S., Yeh, Su-Peng, Jang, Jun Ho, Ozcan, Muhit, Yamamoto, Kazuhito, Illes, Arpad, Zhou, Ying, Dail, Monique, Chyla, Brenda, Potluri, Jalaja, Döhner, Hartmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906463/
https://www.ncbi.nlm.nih.gov/pubmed/34910556
http://dx.doi.org/10.1200/JCO.21.01546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906463/
https://www.ncbi.nlm.nih.gov/pubmed/34910556
http://dx.doi.org/10.1200/JCO.21.01546

Ejemplares similares